slides · global inventory
Clinical Trial Design
Framework collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 129
Current window 91-120
Pages 5
Rows per page 30
Framework
91-120 of 129
13
The slide uses a stepped process diagram to illustrate dose escalation cohorts.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
12
The slide outlines a standard clinical trial progression for SAD and MAD cohorts, including randomization ratios and participant types.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
23
Clinical trial design diagram showing randomization, arms, dosing schedules, and endpoints.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
23
The slide outlines a multi-part clinical trial structure with specific cohort sizes and dosing progression.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
24
The slide outlines a multi-phase clinical trial structure with specific patient cohorts (IMNM, ASyS, DM) and a GO/NO-GO decision point.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations 1 hit
04
The slide uses a timeline-based clinical trial design framework.argenx SE | Investor Presentation Deck | 7 slides · argenx
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
06
The slide outlines a randomized clinical trial structure.argenx SE | Results Presentation Deck | 14 slides · argenx
Conference presentation Investor relations 1 hit
12
The slide uses a standard clinical trial flow diagram showing randomization into three arms (40mg, 20mg, placebo) over a 6-week period.ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
53
The slide details the dose escalation strategy using accelerated, standard, and priming titration cohorts.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
33
The diagram illustrates a standard 3+3 or similar dose escalation design leading to an MTD and subsequent safety expansion.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Market Sizing1 hit
46
The slide outlines a standard oncology clinical trial design (dose escalation followed by expansion).Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
31
The slide outlines a standard clinical trial progression from dose escalation to expansion, with a focus on establishing RP2D and evaluating ORR.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
48
The slide outlines a standard oncology clinical trial design (Phase 1/2) with a transition point at RP2D (Recommended Phase 2 Dose).Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
12
The slide outlines a standard oncology clinical trial design (Phase 1/2) with a transition point at RP2D (Recommended Phase 2 Dose).Exscientia | Results Presentation Deck | 19 slides · Exscientia
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
18
The slide outlines a clinical trial protocol for Olvi-Vec in ovarian cancer.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
28
The diagram illustrates a standard 3+3 or similar dose escalation design.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
32
The diagram illustrates a classic dose-escalation study design.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
37
The slide outlines a standard oncology dose-escalation study design (3+3 or similar) followed by expansion cohorts.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
44
The slide outlines a standard oncology clinical trial design (3+3 or similar dose escalation) followed by cohort expansion.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Loop · Golden Circle1 hit
57
The slide title mentions KT-333, but the content refers to KT-253 throughout; this is likely a typo in the source slide.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
17
The slide outlines a multi-part clinical trial design (basket/umbrella) for a biotech drug candidate.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
13
The slide outlines a multi-part clinical trial process (Part A, Part B, and Expansion) for NSCLC 2L patients.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
18
The slide uses a process flow diagram to illustrate the clinical trial methodology.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
13
Includes a timeline diagram for the randomized, double-blind treatment phase and a summary table of inclusion criteria and endpoints.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
11
Includes details on screen failures and misdiagnosis exclusions.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
26
The slide outlines the RoAD study parameters including patient population, dosing, and primary/secondary endpoints.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
26
The slide outlines the methodology for a Phase 2 clinical trial for Alzheimer's Disease (AD).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
38
The slide outlines a multi-cohort study design with specific patient populations (TKI-naive vs pre-treated) and objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
34
The slide outlines the study design for NVL-655, detailing patient population, objectives, and cohort stratification.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
21
The slide uses a standard clinical trial flow diagram (Population -> Treatment -> Endpoints -> Crossover).RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Loop · Hypothesis Test1 hit